QDEL (QDEL) Stock Analysis
Verdict: AVOID
Crushing $2.83B debt and -$83M FCF offset low 0.28x P/S — key risk is potential debt restructuring dilution before 2027 recovery.
Investment score: 25/100
Is QDEL Stock Worth Reviewing? AI Model Thesis
The AI model rates QDEL as AVOID due to severe balance sheet leverage ($2.83B debt), negative free cash flow, and sustained operating losses (-$919.2M operating income in 2025) that overshadow its ultra-low P/S ratio of 0.28x.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| LNTH | 23.71 | 4.96 | 4.18 | 14.03 | — | 0.18 |
| MMED | -18.36 | 1.57 | 1.76 | 62.05 | — | -0.10 |
| MMSI | 35.82 | 3.12 | 3.32 | 15.50 | — | 0.09 |
| HAE | 51.56 | 5.76 | 3.57 | 22.12 | — | 0.07 |
| ICUI | 138.86 | 1.94 | 1.93 | 17.26 | — | 0.01 |
Should You Buy or Sell QDEL Stock? Model Reasoning
The AI model evaluates QuidelOrtho as high-risk distress exposure. Despite generating $2.73B in 2025 revenue, the company carries $2.83B in debt against $169.8M in cash, while burning -$83M in FCF in 2025. Operating margins stand at -30.7%, and Wall Street analyst revisions remain overwhelmingly skewed toward Hold and Sell ratings.
QDEL Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Consensus EPS recovers to $1.44 by FY2027 as operating losses shrink from -$919.2M toward profitability.","Total debt of $2.83B can be refinanced without highly dilutive equity offerings or debt default.","Gross margins stay supported above 40% (currently 44.6%)."]
QDEL Risk & Opportunity Analysis
Key Investment Risks
- Extreme debt leverage of $2.83B vs $169.8M cash — If operating cash flows fail to cover debt service or capex needs ($188.2M in 2025), the company may require highly dilutive equity offerings or debt restructuring.
- Unsustained free cash flow recovery — Continuous cash burn (-$83M FCF in 2025, -$112.1M in 2024) risks eroding liquidity before 2027 profitability estimates can be achieved.
- Heavy goodwill and asset write-downs — Impairments associated with the Ortho Clinical acquisition ($1.96B operating loss in 2024, -$919.2M in 2025) reflect structural integration friction and asset write-downs.
- Wall Street institutional abandonment — With 4 Sell/Strong Sell ratings vs 1 Buy, analyst downgrades from major houses (Citi, Jefferies) keep institutional capital outflow pressure high.
Growth Opportunities & Upside Drivers
- Deep revenue valuation discount at 0.28x TTM Sales — With $2.73B in annual revenue and a market cap of $733M, any sustained operating margin recovery toward historical 15%+ levels could trigger significant equity re-rating.
- Consensus forward profitability target by 2027 — Analyst estimates project EPS recovery to $1.44 in 2027 and $1.86 in 2028, implying potential for fundamental bottoming if cost-reduction programs succeed.
- Stable gross margins at 44.6% — Gross margin resilience demonstrates underlying pricing power in core lab reagents, providing structural leverage once operational overhead is reduced.
- Substantial installed instrument base — Long-term diagnostic placement contracts in blood banks and clinical labs generate predictable recurring recurring reagent pull-through.
QDEL Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About QDEL (QDEL)
Is QDEL stock a good investment?
The cached TradeMates AI model rates QDEL as AVOID with an investment score of 25/100. The AI model rates QDEL as AVOID due to severe balance sheet leverage ($2.83B debt), negative free cash flow, and sustained operating losses (-$919.2M operating income in 2025) that overshadow its ultra-low P/S ratio of 0.28x. This is algorithmic model output, not personal investment advice.
Does QDEL pay a dividend?
The cached stock data on this page does not show a positive dividend yield for QDEL. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does QDEL stock do?
QuidelOrtho develops, manufactures, and distributes in vitro diagnostic testing solutions globally. Revenue is derived from instrument sales, recurring high-margin reagent sales, and point-of-care test kits across clinical chemistry, immunoassays, transfusion medicine, and molecular diagnostics.
What is QDEL stock's price target?
This cached page does not contain a precise model fair value for QDEL.
Is QDEL stock a buy?
The TradeMates model verdict for QDEL is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.
Is QDEL a good dividend stock?
QDEL is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.